Cerebral, the mental health startup backed by SoftBank, has been hit with layoffs amid an investigation into its prescribing practices and the subsequent decision to stop writing prescriptions for most controlled medications.
Employees who were affected will be notified by July 1st. The decision was confirmed in an email from a spokesman for Cerebral saying that they will double down on quality as part of an effort make the company more efficient
“This process will necessitate difficult decisions to restructure our operations, most notably the elimination of a certain number of roles within the Cerebral team,” the statement read.
A recent news item reported that Cerebral Directors has ousted its CEO amid an investigation into alleged prescription fraud.
